DARE Dare Bioscience (DARE) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001401914
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
17
13F, latest reported quarter
Dare Bioscience insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Dare Bioscience, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
no insider purchases or sales on record
0 transactions on record
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
17 funds bought in last quarter
below 71% of Pharma & Biotech
Revenue
+10429.4% year over year
more than 99% of Pharma & Biotech
Margin
-1300.7% net margin
below 89% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
8.5% of the float short (float per yahoo 2026-10-27) · 10.3 days to cover · settled 2026-10-15
more than 62% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch DARE
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-69.2%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns DARE: institutional holders (13F)
13F holdings, latest reported quarter
640,877 sh
$1.4M
140,093 sh
$295.6K
120,920 sh
$255.1K
91,269 sh
$192.6K
64,248 sh
$135.6K
Congress trades in DARE
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
DARE planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
DARE mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Micro-Cap ETF
$95.6K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$6.3K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$174.1K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$340.5K position · as of 2026-06-30
0.0%
Total Stock Market Index Trust
$1.3K position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$72.4K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Sabrina Martucci Johnson
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$801.1K
$585.9K
$546.9K
-81%
n/a
2024
$898.4K
$754.0K
$455.8K
-69%
n/a
2023
$1.2M
$450.4K
$751.6K
-63%
n/a
2022
$1.7M
$594.2K
$777.5K
-58%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 17 funds added last quarter. Each figure is a federal filing, dated the day it went public.
DARE financials
Revenue growth
+10429.4%
XBRL, annual
Net margin
-1300.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.4M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM DARE
| FY Dec 2025 | $1.0M |
| FY Dec 2024 | $9.8K |
| FY Dec 2023 | $2.8M |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $187.5K |
| Mar 2026 | $152.5K |
| Dec 2025 | $1.0M |
| Sep 2025 | $2.3K |
| Jun 2025 | -$21.2K |
| Mar 2025 | $25.4K |
| Dec 2024 | -$63.6K |
| Sep 2024 | $41.7K |
At each fiscal year end
Single quarter
Net margin, TTM
-804.4%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM DARE
| FY Dec 2025 | -1,301% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -1,074% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | -140.9% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$11.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM DARE
| FY Dec 2025 | -$10.3M |
| FY Dec 2024 | $4.9M |
| FY Dec 2023 | -$39.5M |
| FY Dec 2022 | -$18.2M |
| FY Dec 2021 | -$28.8M |
| Jun 2026 | -$6.9M |
| Mar 2026 | -$5.5M |
| Dec 2025 | $1.2M |
| Sep 2025 | -$616.8K |
| Jun 2025 | -$5.3M |
| Mar 2025 | -$5.6M |
| Dec 2024 | $4.7M |
| Sep 2024 | -$5.6M |
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity DARE
| FY Dec 2025 | 0.00x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | 0.01x |
| Dec 2025 | 0.00x |
| Sep 2025 | 0.00x |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-1,071.29x
TTM operating cash flow over current debt only, 2025-09-30 (9 months older than the period end)
Cash flow to debt DARE
| FY Dec 2025 | -937.76x |
| FY Dec 2024 | 1,350.16x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -1,071.29x |
| Mar 2026 | -942.51x |
| Dec 2025 | -937.76x |
| Sep 2025 | -571.45x |
| Jun 2025 | -61.21x |
| Mar 2025 | 74.16x |
| Dec 2024 | 1,350.16x |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity DARE
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -994.6% |
| FY Dec 2022 | -124.1% |
| FY Dec 2021 | -205.8% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | -2,543% |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-62.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets DARE
| FY Dec 2025 | -49.1% |
| FY Dec 2024 | -18.7% |
| FY Dec 2023 | -92.6% |
| FY Dec 2022 | -62.1% |
| FY Dec 2021 | -122.2% |
| Jun 2026 | -62.2% |
| Mar 2026 | -51.8% |
| Dec 2025 | -49.1% |
| Sep 2025 | -71.5% |
| Jun 2025 | -101.7% |
| Mar 2025 | -10.6% |
| Dec 2024 | -18.7% |
| Sep 2024 | -16.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital DARE
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
capital employed is zero or negative
Return on capital employed DARE
| FY Dec 2025 | -292.2% |
| FY Dec 2024 | -3,636% |
| FY Dec 2023 | -475.8% |
| FY Dec 2022 | -120.8% |
| FY Dec 2021 | -197.1% |
| Jun 2026 | n/a |
| Mar 2026 | -578.2% |
| Dec 2025 | -292.2% |
| Sep 2025 | -242.0% |
| Jun 2025 | -1,332% |
| Mar 2025 | n/a |
| Dec 2024 | -3,636% |
| Sep 2024 | -1,286% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing DARE
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
-$2.8M
market value at close 2026-10-26 on 2026-08-12 shares, plus current debt only, 2025-09-30 (9 months older than the period end), minus cash 2026-06-30
Enterprise value DARE
| FY Dec 2025 | $2.9M |
| FY Dec 2024 | $11.5M |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $19.0M |
| Mar 2026 | $8.0M |
| Dec 2025 | $2.9M |
| Sep 2025 | $5.2M |
| Jun 2025 | $16.3M |
| Mar 2025 | $15.3M |
| Dec 2024 | $11.5M |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-119.4%
TTM free cash flow over market value at close 2026-10-26
FCF yield DARE
| FY Dec 2025 | -37.2% |
| FY Dec 2024 | +18.1% |
| FY Dec 2023 | -10.8% |
| FY Dec 2022 | -2.1% |
| FY Dec 2021 | -1.6% |
| Jun 2026 | -37.2% |
| Mar 2026 | -38.4% |
| Dec 2025 | -37.2% |
| Sep 2025 | -23.9% |
| Jun 2025 | -55.7% |
| Mar 2025 | +23.8% |
| Dec 2024 | +18.1% |
| Sep 2024 | -31.2% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing DARE
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $1.0M | $9.8K | $2.8M | $10.0M |
| Operating income | -$13.6M | -$23.5M | -$30.9M | -$31.4M |
| Net income | -$13.4M | -$4.0M | -$30.2M | -$30.9M |
| EPS (diluted) | -1.20 | -0.48 | -4.15 | -0.37 |
| Operating cash flow | -$9.9M | $5.5M | -$38.9M | -$18.1M |
| Cash | $24.7M | $15.7M | $10.5M | $34.7M |
SEC XBRL, fiscal years, as known on 2026-10-28
DARE Stock Sonar score 4/7 axes
Find similar shapesCompareDARE ranks highest on growth (99th percentile) and risk and compliance (50th), and lowest on financial health (1st), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
